Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Sep 25, 2026, 6:26 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 25–48 of 24 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Intervention: LPCN 1021 Clear all
Active, not recruiting Phase 1 Interventional

Perioperative Testosterone Replacement Therapy for the Improvement of Post-Operative Outcomes in Patients With Low Testosterone

NCT04731376
View directory record Official record
Conditions
Hypogonadism, Malignant Urinary System Neoplasm, Urinary System Disorder, Urinary System Neoplasm
Interventions
Best Practice, Quality-of-Life Assessment, Questionnaire Administration, Testosterone Cypionate
Other · Procedure · Drug
Lead sponsor
Emory University
Other
Eligibility
18 Years and older · Male only
Enrollment
56 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2026
U.S. locations
1
States / cities
Atlanta, Georgia
Source: ClinicalTrials.gov public record
Updated May 25, 2026 · Synced Sep 25, 2026, 6:26 AM EDT
Not listed Phase 4 Interventional

A Study to Monitor Ambulatory Blood Pressure Monitoring in Hypogonadal Men Treated With Nasal Testosterone Gel

NCT04976595
View directory record Official record
Conditions
Hypogonadism
Interventions
Natesto
Drug
Lead sponsor
Acerus Pharmaceuticals Corporation
Industry
Eligibility
18 Years to 80 Years · Male only
Enrollment
218 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2022
U.S. locations
30
States / cities
Birmingham, Alabama • Phoenix, Arizona • Tucson, Arizona + 25 more
Source: ClinicalTrials.gov public record
Updated Jul 5, 2022 · Synced Sep 25, 2026, 6:26 AM EDT
Completed Phase 4 Interventional Results available

A Comparison of Side Effects in Hypogonadal Men Treated With Natesto Versus Testosterone Injections

NCT04439799
View directory record Official record
Conditions
Hypogonadism, Male
Interventions
Testosterone Cypionate 200 Mg/ML, Intranasal Testosterone
Drug
Lead sponsor
University of Miami
Other
Eligibility
18 Years to 75 Years · Male only
Enrollment
81 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2023
U.S. locations
1
States / cities
Miami, Florida
Source: ClinicalTrials.gov public record
Updated Dec 12, 2023 · Synced Sep 25, 2026, 6:26 AM EDT
Terminated Phase 2 Interventional

The Efficacy of ESTRATEST® Tablets in Relieving Menopausal Symptoms in Estrogenized, Non-Hysterectomized Postmenopausal Women

NCT00141544
View directory record Official record
Conditions
Menopause
Interventions
esterified estrogens 1.25 mg and methyltestosterone 2.5 mg, Esterified estrogens 1.25 mg
Drug
Lead sponsor
Solvay Pharmaceuticals
Industry
Eligibility
35 Years to 65 Years · Female only
Enrollment
28 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2008
U.S. locations
78
States / cities
Huntsville, Alabama • Mobile, Alabama • Montgomery, Alabama + 75 more
Source: ClinicalTrials.gov public record
Updated Apr 10, 2008 · Synced Sep 25, 2026, 6:26 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

The Effects of Testosterone on Prostate Tissue (ACYP-1)

NCT00161486
View directory record Official record
Conditions
Hypogonadism, Contraception
Interventions
Testosterone gel, Acyline, Placebo acyline, Placebo Testosterone gel
Drug
Lead sponsor
University of Washington
Other
Eligibility
35 Years to 55 Years · Male only
Enrollment
13 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2004
U.S. locations
1
States / cities
Seattle, Washington
Source: ClinicalTrials.gov public record
Updated Sep 18, 2008 · Synced Sep 25, 2026, 6:26 AM EDT
Not listed Phase 2 Interventional

Deslorelin Combined With Low-Dose Add-Back Estradiol and Testosterone in Preventing Breast Cancer in Premenopausal Women Who Are at High Risk for This Disease

NCT00080756
View directory record Official record
Conditions
brca1 Mutation Carrier, brca2 Mutation Carrier, Breast Cancer
Interventions
therapeutic estradiol, deslorelin, therapeutic testosterone, therapeutic conventional surgery, active surveillance, quality-of-life assessment, laboratory biomarker analysis
Biological · Drug · Procedure + 1 more
Lead sponsor
City of Hope Medical Center
Other
Eligibility
21 Years to 48 Years · Female only
Enrollment
11 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2024
U.S. locations
1
States / cities
Duarte, California
Source: ClinicalTrials.gov public record
Updated Aug 27, 2024 · Synced Sep 25, 2026, 6:26 AM EDT
Completed Phase 1 Interventional Results available

Testosterone for Treating Cachexia in Patients With Squamous Cell Carcinoma

NCT00878995
View directory record Official record
Conditions
Cachexia, Squamous Cell Carcinoma
Interventions
Placebo Testosterone, Testosterone Enanthate 100 MG/ML
Drug
Lead sponsor
The University of Texas Medical Branch, Galveston
Other
Eligibility
18 Years to 75 Years · Female only
Enrollment
28 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2015
U.S. locations
1
States / cities
Galveston, Texas
Source: ClinicalTrials.gov public record
Updated Mar 11, 2018 · Synced Sep 25, 2026, 6:26 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Influence of Male Hormones on Regional Fat Metabolism

NCT01160328
View directory record Official record
Conditions
Obesity
Interventions
Leuprolide, Testosterone
Drug
Lead sponsor
Mayo Clinic
Other
Eligibility
18 Years to 50 Years · Male only
Enrollment
39 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2010 – 2013
U.S. locations
1
States / cities
Rochester, Minnesota
Source: ClinicalTrials.gov public record
Updated May 13, 2014 · Synced Sep 25, 2026, 6:26 AM EDT
Recruiting Phase 3 Interventional

52 Week Study + 24-Month Long-Term Extension of Safety, PK, & Efficacy of XYOSTED® for Testosterone Replacement in Male Adolescents With Hypogonadism

NCT06689085
View directory record Official record
Conditions
Hypogonadism, Male
Interventions
Testosterone enanthate
Combination Product
Lead sponsor
Halozyme Therapeutics
Industry
Eligibility
12 Years to 17 Years · Male only
Enrollment
100 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2030
U.S. locations
20
States / cities
Los Angeles, California • San Diego, California • San Francisco, California + 17 more
Source: ClinicalTrials.gov public record
Updated Feb 17, 2026 · Synced Sep 25, 2026, 6:26 AM EDT
Active, not recruiting Phase 2 Interventional

The Anabolic Effect of Testosterone on Pelvic Floor Muscles

NCT06111209
View directory record Official record
Conditions
Stress Urinary Incontinence, Menopause
Interventions
Testosterone cypionate, Placebo
Drug
Lead sponsor
Brigham and Women's Hospital
Other
Eligibility
60 Years and older · Female only
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2027
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Jun 25, 2026 · Synced Sep 25, 2026, 6:26 AM EDT
Withdrawn Phase 2Phase 3 Interventional

Effect of Testosterone Replacement on Exercise Capacity in Hypogonadal Men After a Recent Myocardial Infarction

NCT02803073
View directory record Official record
Conditions
Hypogonadism, Acute Myocardial Infarction: Rehabilitation Phase
Interventions
Testosterone, Normal Saline
Drug
Lead sponsor
Texas Tech University Health Sciences Center
Other
Eligibility
18 Years and older · Male only
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2017
U.S. locations
1
States / cities
Odessa, Texas
Source: ClinicalTrials.gov public record
Updated Nov 20, 2019 · Synced Sep 25, 2026, 6:26 AM EDT
Completed Phase 3 Interventional Results available

Testosterone Replacement for Fatigue in Male Hypogonadic Advanced Cancer Patients

NCT00965341
View directory record Official record
Conditions
Advanced Cancer
Interventions
Testosterone, Placebo
Drug
Lead sponsor
M.D. Anderson Cancer Center
Other
Eligibility
18 Years and older · Male only
Enrollment
53 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2012
U.S. locations
2
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Sep 12, 2016 · Synced Sep 25, 2026, 6:26 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers Results available

Evaluate the Pharmacokinetics and Gonadotropin Suppression of Nestorone®-Testosterone (NES/T) Combination Gel in Men

NCT02432261
View directory record Official record
Conditions
Healthy
Interventions
Nestorone® /testosterone gel, Testosterone only gel
Drug
Lead sponsor
Kimberly Myer
Other
Eligibility
18 Years to 50 Years · Male only
Enrollment
44 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2015 – 2016
U.S. locations
2
States / cities
Torrance, California • Seattle, Washington
Source: ClinicalTrials.gov public record
Updated Feb 12, 2025 · Synced Sep 25, 2026, 6:26 AM EDT
Completed Phase 3 Interventional Results available

Subcutaneous Testosterone Replacement Efficacy and Safety in Adult Men Diagnosed With Hypogonadism

NCT02159469
View directory record Official record
Conditions
Hypogonadism
Interventions
Testosterone enanthate auto-injector
Combination Product
Lead sponsor
Antares Pharma Inc.
Industry
Eligibility
18 Years and older · Male only
Enrollment
150 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2015
U.S. locations
28
States / cities
Birmingham, Alabama • Huntsville, Alabama • Tucson, Arizona + 25 more
Source: ClinicalTrials.gov public record
Updated Feb 6, 2018 · Synced Sep 25, 2026, 6:26 AM EDT
Terminated Phase 1Phase 2 Interventional Results available

A Phase 1/2a Study to Determine the Dose Response Pharmacokinetics of TSX-011 (Testosterone Undecanoate) in Hypogonadal Males

NCT03335254
View directory record Official record
Conditions
Hypogonadism, Hypogonadism, Male, Gonadal Disorders, Endocrine System Diseases, Testosterone Deficiency
Interventions
TSX-011
Drug
Lead sponsor
TesoRx Pharma, LLC
Industry
Eligibility
18 Years to 75 Years · Male only
Enrollment
9 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2018
U.S. locations
1
States / cities
Glendale, California
Source: ClinicalTrials.gov public record
Updated May 15, 2019 · Synced Sep 25, 2026, 6:26 AM EDT
Completed Phase 4 Interventional Accepts healthy volunteers Results available

Influence of Testosterone Administration on Drug-Induced QT Interval Prolongation and Torsades de Pointes

NCT02513940
View directory record Official record
Conditions
Long QT Syndrome
Interventions
Testosterone, Progesterone, Placebo, Ibutilide
Drug
Lead sponsor
Indiana University
Other
Eligibility
65 Years and older · Male only
Enrollment
14 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2016 – 2017
U.S. locations
1
States / cities
Indianapolis, Indiana
Source: ClinicalTrials.gov public record
Updated Aug 27, 2019 · Synced Sep 25, 2026, 6:26 AM EDT
Completed Phase 4 Interventional Accepts healthy volunteers Results available

TRADE-Testosterone Replacement and Dutasteride Effectiveness

NCT00194675
View directory record Official record
Conditions
Hypogonadism, Benign Prostatic Hyperplasia
Interventions
Dutasteride, Testosterone gel, Placebo dutasteride
Drug
Lead sponsor
University of Washington
Other
Eligibility
50 Years and older · Male only
Enrollment
53 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2005 – 2010
U.S. locations
1
States / cities
Seattle, Washington
Source: ClinicalTrials.gov public record
Updated Dec 4, 2017 · Synced Sep 25, 2026, 6:26 AM EDT
Completed Phase 1 Interventional

Muscle Anabolic Interventions to Accelerate Recovery From Hospitalization in Geriatric Patients

NCT02990533
View directory record Official record
Conditions
Aging
Interventions
Testosterone, Protein Supplement, Placebo Injection, Placebo supplement
Drug · Dietary Supplement · Other
Lead sponsor
The University of Texas Medical Branch, Galveston
Other
Eligibility
65 Years and older
Enrollment
80 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2020
U.S. locations
1
States / cities
Galveston, Texas
Source: ClinicalTrials.gov public record
Updated Dec 16, 2024 · Synced Sep 25, 2026, 6:26 AM EDT
Completed Phase 4 Interventional

Vogelxo(R) ABPM Study in Hypogandal Men

NCT04558567
View directory record Official record
Conditions
Hypogonadism, Male
Interventions
Vogelxo
Drug
Lead sponsor
Upsher-Smith Laboratories
Industry
Eligibility
18 Years to 80 Years · Male only
Enrollment
122 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2024
U.S. locations
7
States / cities
Birmingham, Alabama • Anaheim, California • Miami, Florida + 3 more
Source: ClinicalTrials.gov public record
Updated Oct 17, 2024 · Synced Sep 25, 2026, 6:26 AM EDT
Completed Phase 2 Interventional

Study of the Efficacy of ESTRATEST® H.S. Tablets in Relieving Menopausal Symptoms in Estrogenized Postmenopausal Women

NCT00141570
View directory record Official record
Conditions
Menopause
Interventions
esterified estrogens 0.625 mg and methyltestosterone 1.25 mg
Drug
Lead sponsor
Solvay Pharmaceuticals
Industry
Eligibility
30 Years to 65 Years · Female only
Enrollment
350 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2007
U.S. locations
77
States / cities
Huntsville, Alabama • Mobile, Alabama • Montgomery, Alabama + 74 more
Source: ClinicalTrials.gov public record
Updated Jan 15, 2015 · Synced Sep 25, 2026, 6:26 AM EDT
Terminated Phase 2 Interventional

The Efficacy of ESTRATEST® Tablets in Relieving Menopausal Symptoms in Estrogenized, Hysterectomized Postmenopausal Women

NCT00141557
View directory record Official record
Conditions
Menopause
Interventions
esterified estrogens 1.25mg and methyltestosterone 2.5mg, Esterified estrogens 1.25 mg
Drug
Lead sponsor
Solvay Pharmaceuticals
Industry
Eligibility
35 Years to 65 Years · Female only
Enrollment
133 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2008
U.S. locations
78
States / cities
Huntsville, Alabama • Mobile, Alabama • Montgomery, Alabama + 75 more
Source: ClinicalTrials.gov public record
Updated Apr 10, 2008 · Synced Sep 25, 2026, 6:26 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers Results available

Cycled Testosterone Replacement Study

NCT00957528
View directory record Official record
Conditions
Hypogonadism
Interventions
Testosterone, Placebo
Drug
Lead sponsor
The University of Texas Medical Branch, Galveston
Other
Eligibility
60 Years to 85 Years · Male only
Enrollment
26 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2006 – 2008
U.S. locations
1
States / cities
Galveston, Texas
Source: ClinicalTrials.gov public record
Updated Sep 9, 2012 · Synced Sep 25, 2026, 6:26 AM EDT
Not yet recruiting Phase 2Phase 3 Interventional

Testosterone Therapy With or Without Finasteride After Spinal Cord Injury: TRT-SCI Trial

NCT07742553
View directory record Official record
Conditions
Spinal Cord Injury, Spinal Cord Injuries, Injuries, Spinal Cord, Spinal Cord Contusion, Spinal Cord Trauma, Trauma, Nervous System, Wounds and Injuries, Spinal Cord Compression, Nervous System Diseases, Spinal Cord Diseases, Gonadal Disorders, Endocrine System Diseases, Hypogonadism, Genital Diseases, Male
Interventions
testosterone cypionate, finasteride, placebo injection, placebo pill
Drug
Lead sponsor
VA Office of Research and Development
Federal
Eligibility
18 Years and older · Male only
Enrollment
300 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2027 – 2032
U.S. locations
4
States / cities
Aurora, Colorado • Gainesville, Florida • Tampa, Florida + 1 more
Source: ClinicalTrials.gov public record
Updated Aug 3, 2026 · Synced Sep 25, 2026, 6:26 AM EDT
Not listed Phase 1Phase 2 Interventional

TRT in Combination With Electrical Stimulation and Standing: Effect on Muscle and Bone in Spinal Cord Injured Males

NCT02317640
View directory record Official record
Conditions
Spinal Cord Injury
Interventions
Testosterone Gel applied by a pump, Stand Training, Electrical Stimulation
Drug · Other · Device
Lead sponsor
Kessler Foundation
Other
Eligibility
18 Years to 58 Years · Male only
Enrollment
56 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2022
U.S. locations
1
States / cities
West Orange, New Jersey
Source: ClinicalTrials.gov public record
Updated Aug 21, 2017 · Synced Sep 25, 2026, 6:26 AM EDT